Patents by Inventor Norifumi Nakamura
Norifumi Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11959197Abstract: A first aspect of the present invention is carbon fiber wherein the surface of a monofilament has a center line average roughness Ra of 6.0 nm or more and 13 nm or less, and the monofilament has a long diameter/short diameter ratio of 1.11 or more and 1.245 or less. A second aspect of the present invention is carbon fiber precursor acrylic fiber wherein the surface of a monofilament has a center line average roughness Ra of 18 nm or more and 27 nm or less, and the monofilament has a long diameter/short diameter ratio of 1.11 or more and 1.245 or less. The carbon fiber according to the first aspect is obtained by stabilizing and carbonizing under specific conditions the carbon fiber precursor acrylic fiber according to the second aspect.Type: GrantFiled: August 15, 2019Date of Patent: April 16, 2024Assignee: Mitsubishi Chemical CorporationInventors: Naomasa Matsuyama, Yuutarou Nakamura, Norifumi Hirota, Hiroko Matsumura, Katsuhiko Ikeda, Kouki Wakabayashi, Tadashi Ootani, Akihiro Itou, Kenji Hirano, Akito Hatayama, Kenji Kaneta, Atsushi Nakajima
-
Patent number: 8362059Abstract: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.Type: GrantFiled: August 19, 2011Date of Patent: January 29, 2013Assignee: Topica Pharmaceuticals, Inc.Inventors: Charles G. Vontz, Norifumi Nakamura, Catherine de Porceri-Morton, Jeff Hughes, Bhavesh Shah, Peter Gertas, Vitthal Kulkarni
-
Patent number: 8193232Abstract: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.Type: GrantFiled: February 12, 2010Date of Patent: June 5, 2012Assignee: Topica Pharmaceuticals, Inc.Inventors: Charles G. Vontz, Norifumi Nakamura, Catherine de Porceri-Morton, Jeff Hughes, Bhavesh Shah, Peter Gertas, Vitthal Kulkarni
-
Patent number: 8193233Abstract: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.Type: GrantFiled: March 30, 2010Date of Patent: June 5, 2012Assignee: Topica Pharmaceuticals, Inc.Inventors: Charles G. Vontz, Norifumi Nakamura, Catherine de Porceri-Morton, Jeff Hughes, Bhavesh Shah, Peter Gertas, Vitthal Kulkarni
-
Publication number: 20120071533Abstract: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.Type: ApplicationFiled: August 19, 2011Publication date: March 22, 2012Inventors: Charles G. VONTZ, Norifumi Nakamura, Catherine de Porceri-Morton, Jeff Hughes, Bhavesh Shah, Peter Gertas, Vitthal Kulkarni
-
Publication number: 20100210702Abstract: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.Type: ApplicationFiled: February 12, 2010Publication date: August 19, 2010Applicant: Topica Pharmaceuticals, Inc.Inventors: Charles G. VONTZ, Norifumi Nakamura, Catherine de Porceri-Morton, Jeff Hughes, Bhavesh Shah, Peter Gertas, Vitthal Kulkarni
-
Publication number: 20100210703Abstract: Provided herein are compositions and formulations comprising an antifungal agent. Pharmaceutical compositions comprising luliconazole in an amount effective for the treatment of onychomycosis are provided. Also provided are methods for treating dermatomycoses and onychomycosis using the compositions and formulations.Type: ApplicationFiled: March 30, 2010Publication date: August 19, 2010Inventors: Charles G. Vontz, Norifumi Nakamura, Catherine de Porceri-Morton, Jeff Hughes, Bhavesh Shah, Peter Gertas, Vitthal Kulkarni
-
Publication number: 20030203354Abstract: A method for screening an apoptosis inhibitor characterized by screening a candidate via an effect on PGT. A cell protecting agent containing as the active ingredient a substance which can be incorporated into cells via prostaglandin transporter (PGT); and a screening method therefor comprising measuring the uptake into cells via PGT. An apoptosis inducer containing as the active ingredient a substance having a PGT inhibitory effect; and a screening method therefor comprising measuring the ability to induce apoptosis of cells with the expression of PGT. Because of having a cell apoptosis inhibitory effect, the cell protecting agent is useful as a nerve cell apoptosis inhibitor, a nerve cell protecting agent, etc. and applicable to the prevention or treatment of nervous diseases, etc. The apoptosis inducer is useful in preventing and/or treating diseases in association with cell proliferation such as tumor, etc.Type: ApplicationFiled: June 11, 2003Publication date: October 30, 2003Applicant: MITSUBISHI PHARMA CORPORATIONInventors: Tooru Kawamura, Satoshi Horie, Toshiaki Akira, Norifumi Nakamura, Tomoyuki Maruyama, Kazutaka Hayashi
-
Publication number: 20020127228Abstract: A method for screening an apoptosis inhibitor characterized by screening a candidate via an effect on PGT. A cell protecting agent containing as the active ingredient a substance which can be incorporated into cells via prostaglandin transporter (PGT); and a screening method therefor comprising measuring the uptake into cells via PGT. An apoptosis inducer containing as the active ingredient a substance having a PGT inhibitory effect; and a screening method therefor comprising measuring the ability to induce apoptosis of cells with the expression of PGT. Because of having a cell apoptosis inhibitory effect, the cell protecting agent is useful as a nerve cell apoptosis inhibitor, a nerve cell protecting agent, etc. and applicable to the prevention or treatment of nervous diseases, etc. The apoptosis inducer is useful in preventing and/or treating diseases in association with cell proliferation such as tumor, etc.Type: ApplicationFiled: June 4, 2001Publication date: September 12, 2002Applicant: WELFIDE CORPORATIONInventors: Tooru Kawamura, Satoshi Horie, Toshiaki Akira, Norifumi Nakamura, Tomoyuki Maruyama, Kazutaka Hayashi
-
Patent number: 6369061Abstract: A therapeutic agent for spinal canal stenosis is provided, which contains a pyridazinone compound of the formula (I) wherein R1, R2 and R3 are each independently a hydrogen atom or a lower alkyl, X is a halogen atom, a cyano or a hydrogen atom, Y is a halogen atom, a trifluoromethyl or a hydrogen atom, and A is a C1-C8 alkylene optionally substituted with a hydroxyl, or its pharmacologically acceptable salt.Type: GrantFiled: March 21, 2001Date of Patent: April 9, 2002Assignees: Mitsubishi Pharma Corporation, Nissan Chemical Industries, Ltd.Inventors: Tomoyuki Maruyama, Toru Kawamura, Toshiaki Akira, Hideaki Kido, Norifumi Nakamura
-
Patent number: 6284758Abstract: An angiogenesis promoter and angiogenesis potentiator containing a pyridazinone compound of the formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof, as an active ingredient. The pyridazinone compound (I) and a pharmacologically acceptable salt thereof in the present invention promote angiogenesis and potentiate the angiogenic effect of a drug having such effect, and are useful as an angiogenesis promoter and angiogenesis potentiator.Type: GrantFiled: February 25, 2000Date of Patent: September 4, 2001Assignees: Welfide Corporation, Nissan Chemical Industries, Ltd.Inventors: Yasuhiro Egi, Hideaki Kido, Kazutaka Hayashi, Yoshiji Kubo, Norifumi Nakamura
-
Patent number: 6060480Abstract: An agent for the prophylaxis or treatment of muscle tissue degeneration, containing, as an active ingredient, a quinoline compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt. The prophylactic or therapeutic agent of muscle tissue degeneration of the present invention contains a quinoline compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and shows remarkable inhibitory or improving action on degeneration of the muscle tissues such as necrosis, fibrosis, calcification and the like. The agent is specifically useful for the prophylaxis and treatment of cardiomyopathy, muscular dystrophy, pulmonary fibrosis and the like.Type: GrantFiled: May 10, 1999Date of Patent: May 9, 2000Assignees: Yoshitomi Pharmaceutical Industries, Ltd., Asahi Glass Co., Ltd.Inventors: Norifumi Nakamura, Mamoru Koyama, Mizuo Miyazaki
-
Patent number: 5798357Abstract: An agent for the prophylaxis or treatment of TXA.sub.2 -mediated diseases, particularly, a TXA.sub.2 synthetase inhibitor, which comprises a pyridazinone compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof as an active ingredient. The pyridazinone compound (I) and pharmacologically acceptable salts thereof used in the present invention have prophylactic and therapeutic activities against TXA.sub.2 -mediated diseases, particularly a TXA.sub.2 synthetase inhibitory action and are useful as an agent for the prophylaxis or treatment of TXA.sub.2 -mediated diseases, particularly as TXA.sub.2 synthetase inhibitors.Type: GrantFiled: August 8, 1996Date of Patent: August 25, 1998Assignees: The Green Cross Corporation, Nissan Chemical Industries, Ltd.Inventors: Ruriko Ikegawa, Teruaki Imada, Norifumi Nakamura, Keizo Tanikawa, Nobutomo Tsuruzoe
-
Patent number: 5780634Abstract: Quinolin-2-yl benzoic acid compounds which are useful as intermediates of quinoline compounds having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds in which a carboxyl group bonded to a phenyl group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction.Type: GrantFiled: October 27, 1995Date of Patent: July 14, 1998Assignees: The Green Cross Corporation, Asahi Glass Co., Ltd.Inventors: Yoshihisa Inoue, Hajime Ebisu, Naomichi Ishida, Norifumi Nakamura, Jun Sasaki, Takashi Okazoe, Yoshitomi Morizawa, Arata Yasuda, Shuzhong Wang, Tomoko Ito
-
Patent number: 5753670Abstract: A novel carboxylic acid compound having a condensed ring; which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.Type: GrantFiled: March 26, 1997Date of Patent: May 19, 1998Assignee: The Green Cross CorporationInventors: Shinichiro Ono, Tomohiro Yoshida, Atsuyuki Ashimori, Keigo Kosaka, Takehiro Okada, Kazuhiro Maeda, Masahiro Eda, Fumio Mori, Yoshihisa Inoue, Hajime Ebisu, Teruaki Imada, Ruriko Ikegawa, Feng Wang, Norifumi Nakamura
-
Patent number: 5665881Abstract: A quinoline compound represented by the formula (1) or a salt thereof: ##STR1## wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.Type: GrantFiled: October 10, 1995Date of Patent: September 9, 1997Assignees: The Green Cross Corporation, Asahi Glass Co., Ltd.Inventors: Yoshihisa Inoue, Hajime Ebisu, Naomichi Ishida, Norifumi Nakamura, Jun Sasaki, Takashi Okazoe, Yoshitomi Morizawa, Arata Yasuda
-
Patent number: 5635527Abstract: A novel carboxylic acid compound having a condensed ring, which is represented by the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmacologically acceptable salt thereof, a pharmaceutical composition thereof and pharmaceutical use thereof. The novel carboxylic acid compound having a condensed ring and pharmacologically acceptable salt thereof of the present invention have superior GPIIb/IIIa antagonism in mammals inclusive of human; can be administered orally; have long life in blood and low toxicity; and show less side-effects. Accordingly, they are extremely useful for the prophylaxis and treatment of thrombotic diseases and other diseases.Type: GrantFiled: February 6, 1996Date of Patent: June 3, 1997Assignee: The Green Cross CorporationInventors: Shinichiro Ono, Tomohiro Yoshida, Atsuyuki Ashimori, Keigo Kosaka, Takehiro Okada, Kazuhiro Maeda, Masahiro Eda, Fumio Mori, Yoshihisa Inoue, Hajime Ebisu, Teruaki Imada, Ruriko Ikegawa, Feng Wang, Norifumi Nakamura
-
Patent number: 5530001Abstract: A novel pharmaceutical use of a dihydropyridine derivative of the formula (I) ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and each is an alkyl or the like; R.sub.4 is a hydrogen atom or the like; R.sub.5 is nitro, a halogenated alkyl, cyano or the like; X is a vinylene or an azomethine; A is an alkylene; and B is --N(R.sub.6) (R.sub.7) or a group of the formula ##STR2## wherein R.sub.6 and R.sub.7 are the same or different and each is an alkyl, an aralkyl, an aryl or the like; R.sub.8 and Ar are aryl or the like; and n is 0, 1 or 2, or an acid addition salt thereof for promoting PGI.sub.2 production, and for the treatment and prevention of hyperlipemia, arteriosclerosis and cerebral diseases.Type: GrantFiled: February 24, 1995Date of Patent: June 25, 1996Assignee: The Green Cross CorporationInventors: Masahide Nakajima, Norifumi Nakamura, Feng Wang, Koichi Yamanouchi, Kazutaka Hayashi, Hideaki Kido, Yoshiji Kubo, Minori Okita, Takeshi Uchida, Masahiro Watanabe, Katsumi Yamanaga, Hiroshi Shinyama, Toru Kawamura, Yuji Narita
-
Patent number: 5478832Abstract: A quinoline compound represented by the formula (1) or a salt thereof: ##STR1## wherein the definition of each substituents are described in the specification, which have angiotensin II antagonism and hypotensive action and are useful as an agent for the prevention and treatment of cardiovascular system diseases such as hypertension, heart failure and the like.Type: GrantFiled: May 4, 1993Date of Patent: December 26, 1995Assignees: The Green Cross Corporation, Asahi Glass Co., Ltd.Inventors: Yoshihisa Inoue, Hajime Ebisu, Naomichi Ishida, Norifumi Nakamura, Jun Sasaki, Takashi Okazoe, Yoshitomi Morizawa, Arata Yasuda
-
Patent number: 5387684Abstract: An isoindazole compound of the formula (1) or a salt thereof; a method for the production thereof; and pharmaceutical use of the compound and a salt thereof, particularly as an angiotensin II antagonist and as an agent for the prophylaxis and treatment of circulatory diseases (particularly hypertension and heart failure); ##STR1## wherein Q is a heterocyclic derivative of the formula (2) or (3) ##STR2## wherein other symbols of the above formulas are as defined in the Specification. The compound and its salt show superior angiotensin II antagonism and are low toxic. Accordingly, they are useful as angiotensin II antagonists for the treatment or prophylaxis of angiotensin II-mediated diseases such as circulatory diseases of hypertension (e.g. essential hypertension, renal hypertension) and heart failure.Type: GrantFiled: January 24, 1994Date of Patent: February 7, 1995Assignees: The Green Cross Corporation, Asahi Glass Co., Ltd.Inventors: Yoshihisa Inoue, Hajime Ebisu, Norifumi Nakamura, Yoshitomi Morizawa, Takashi Okazoe, Arata Yasuda